Month: December 2020

CELEBRATION, Fla., Dec. 22, 2020 (GLOBE NEWSWIRE) — KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin human clinical trials of KP879. KemPharm is developing KP879 as an extended-duration, agonist replacement therapy for the treatment of Stimulant Use Disorder (SUD).If the KP879 IND filing is accepted by the FDA, KemPharm intends to initiate efficacy studies of KP879 in 2021. It is anticipated that certain data from previously completed KP415 research may be leveraged for KP879, including pharmacokinetic studies, which KemPharm believes could potentially streamline the development timeline of KP879. KP879 utilizes serdexmethylphenidate...

CHICAGO, Dec. 22, 2020 (GLOBE NEWSWIRE) — Potbelly Corporation (NASDAQ: PBPB), the iconic neighborhood sandwich shop, today announced the appointment of Adiya Dixon as Chief Legal Officer and Secretary. In this role, Ms. Dixon will serve as in house legal advisor to the Company’s executive team and Board of Directors on legal business issues. She will also manage all legal matters across the organization including regulatory compliance, risk mitigation, business transactions, litigation, real estate and franchisee business as well as corporate securities.Bob Wright, President and Chief Executive Officer of Potbelly commented, “I’m excited to welcome Adiya to her new role at Potbelly. She is a terrific attorney with the broad business experience that is a perfect fit for Potbelly’s needs as we exit this pandemic and return our focus...

MONTREAL, Dec. 22, 2020 (GLOBE NEWSWIRE) — Vanstar Mining Resources (TSX.V – VSR) is pleased to provide a recap of exploration activities that took place on its mining properties and in its joint venture during the year 2020.Nelligan ProjectIt has been a busy year on the Nelligan project starting with an 8,000 m drilling campaign to verify the western and deep extension of the Renard zone as well as to improve resource classification. The first results were reported in June: 10.5M at 10.5 g/t Au confirming the West extension of the mineralization of the Nelligan Project. More results were reported in August (39.1M grading 2.14 g/t Au) and in December (17.3M grading 7.62 g/t Au). Drilling extended the Nelligan deposit to the west by approximately 700 m, representing a sizable step out and extension of the known deposit area....

CALGARY, Alberta, Dec. 22, 2020 (GLOBE NEWSWIRE) — Acceleware® Ltd. (“Acceleware” or the “Company”) (TSXV: AXE), a leading developer of technologies targeting low-cost and clean extraction of heavy oil and bitumen, including enabling the development of low-carbon initiatives, is pleased to announce that a second major oil sands producer (the “Producer”) has agreed to provide financial and technical support for the commercial-scale pilot test of its RF XL radio frequency heating system at Marwayne, Alberta. The Producer will provide funding of $2 million and technical expertise in support of the Marwayne RF XL pilot under the terms of an agreement with Acceleware.In exchange for the funding, the Producer will be able to provide input into pilot designs and test specifications prior to completion, and will receive, along with the...

Selskabsmeddelelse nr. 32-2020Odense, den 22. december 2020Odico A/S har modtaget en stævning fra en tidligere kapitalejer.Odico modtog i 2018 et krav fra en tidligere kapitalejer i Odico, som oplyst i selskabsmeddelelse nr. 2-2018 af 21. juni 2018. Som oplyst i virksomhedsbeskrivelsen, der blev offentliggjort den 7. juni 2018, blev der indgået en forligsaftale med samme person omkring betaling af et beløb på 2,2 mio.kr.Som nævnt i årsrapporten for 2019/20, blev der i regnskabsåret 2017/18 hensat 2,2 mio.kr. til dækning af forligsaftalen. Beløbet er betalt i henhold til forligsaftalen og Odico anser således sagen for afsluttet.Odico er nu blevet stævnet af samme kapitalejer, baseret på den tidligere sag.Odico anser det nye krav for grundløst og betragter fortsat opfyldelsen af forligsaftalen i juli 2020, som afslutning på aftalen med...

SHANGHAI, China, Dec. 22, 2020 (GLOBE NEWSWIRE) — Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced today the appointment of Lan Kang to the Company’s Board of Directors as a non-executive director. Ms. Kang has more than two decades of experience in the life sciences industry with significant expertise building and leading key business development and operations functions at global companies.“Ms. Kang’s broad corporate leadership and track record of success as a life sciences business leader will be invaluable to Everest Medicines as the Company continues to advance its robust portfolio of novel, clinical-stage drug candidates and simultaneously...

中国上海, Dec. 22, 2020 (GLOBE NEWSWIRE) — 家专注于创新药开发及商业化的生物制药公司，致力于满足中国（含香港、澳门以及台湾地区）及亚洲其他市场尚未满足的医疗需求，今天宣布任命康岚女士为公司董事会非执行董事。康女士拥有超过二十年的生命科学行业经验，在跨国公司中积累了丰富的专业知识，并领导了重要的业务发展和运营职能。云顶新耀董事会主席、康桥资本首席执行官傅唯表示：“康岚女士广泛的企业领导能力以及作为生命科学业务领导者的成功经验对于云顶新耀来说是非常宝贵的。公司将持续推进其强大的临床阶段候选创新药物组合，同时不断提升其作为致力于满足大中华区和其他新兴亚太市场尚未满足的医疗需求的全球领导者地位。”康岚女士表示：“我很高兴能加入这个优秀敬业的行业领导者团队。我们将共同努力，建立并加速全球创新药物与中国患者的联系，并给本地区带来更广泛的创新疗法。”康女士曾在复星国际担任多个职位，包括复星国际执行董事会董事及高级副总裁，负责复星保险业务并担任复星人力资源负责人。彼亦曾任多家医疗健康企业（包括复星医药及复星联合健康保险）的非执行董事会董事。在加入复星之前，康女士曾在中国麦肯锡咨询公司工作五年时间，并曾在其职业生涯早期担任肿瘤研究科学家。康女士目前担任康桥资本集团C-Bridge Value Creation Limited的董事总经理。康女士获得了浙江大学生物科学与技术学士学位以及宾夕法尼亚大学沃顿商学院的医疗管理工商管理硕士荣誉学位，并获得了美国路易斯安那州杜兰大学的生物化学硕士学位。有关云顶新耀云顶新耀是一家专注于创新药开发及商业化的生物制药公司，致力于满足大中华区及亚洲其他市场尚未满足的医疗需求。云顶新耀的管理团队在国内外高质量临床开发、药政事务、化学制造与控制(CMC)、业务发展和运营方面拥有深厚的专长和丰富的经验。云顶新耀已打造了8款有潜力成为全球同类首创或者同类最佳的药物组合，其中大部分已经处于临床试验后期阶段。公司的治疗领域包括肿瘤、自体免疫性疾病、心肾疾病和感染性疾病。有关更多信息，请访问公司网站：...

December 22, 2020 07:10 ET | Source: DFDS A/S multilang-releaseCompany announcement Each employee is awarded 50 shares in recognition of their contribution in a year with exceptional challenges. The award is exempt for managers with existing sharebased remuneration. The 50 shares will vest over a three year period thereby incentivising employees in coming years. The total number of employees eligible for the award of shares is around 8,000 and the total value of awarded shares is around DKK 110m at today’s share price. “Our employees have been through an exceptionally challenging year. To show our appreciation of their contribution to DFDS and to our customers as well as to strengthen the bond with our employees, Management and the Board of Directors have decided to award 50 shares to all employees. The shares will vest over...